• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Blogs » BioWorld MedTech Perspectives » Boston Scientific flies the W flag

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech / Earnings

Boston Scientific flies the W flag

April 28, 2016
By Amanda Pedersen

CubsGoatIt took 10 years but Boston Scientific (BSX) may have finally overcome its ill-advised 2006 Guidant acquisition. The company’s shares hit a decade high Wednesday, at one point spiking nearly 12 percent to $22.05 after knocking its first quarter sales out of the park.

Listening to the earnings call, the baseball fan in me couldn’t help but draw comparisons between the company’s better-than-expected earnings and what is already a record-setting season for the Chicago Cubs. Sure, it seemed like a stretch at first, but the more I thought about it the more the analogy made sense. After all, the Cubs have the alleged goat curse and Boston Scientific has Guidant.

But it was the Q&A exchange between J.P. Morgan’s Mike Weinstein and BSX execs that really made me think of the 2016 Cubbies.

Weinstein: So, when’s the last time Boston Scientific grew 8 percent organic? You guys know the answer?

CEO Michael Mahoney: I’ll bet you Dan knows. I don’t.

CFO Dan Brennan: I’d say 10 years, Mike.

Weinstein: 2Q 2005.

Brennan: That’s right.

Mahoney: There you go. Let’s do it again.

I had to laugh at that point because I could picture Cubs manager Joe Maddon standing in a corporate board room saying exactly that to Boston Scientific’s executive team. And then he would throw a company-wide pajama party to celebrate, because that’s how Maddon rolls.

But seriously, Boston Scientific's first quarter is worthy of flying the W flag (the victory flag flown at Wrigley Field after every Chicago Cubs home win). And given the lineup of recently-approved products, this could be a real turning point for the company. Funny, the same could be said of this year's baseball season as the Cubs just celebrated its best 20-game start since 1907.

(Note to Editor: Please forgive my excessive Cubs references. This post may be the last time I find an excuse to write about baseball for Medical Device Daily Perspectives, I had to make it count.)

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 29, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 29, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 29, 2025
  • Illustration of Microglia cells (red) in Alzheimer´s disease

    Two cancer drugs combined modify Alzheimer’s disease in mice

    BioWorld
    Current treatments for Alzheimer’s disease have limited effects. While they can slow cognitive decline or alleviate symptoms, they do not reverse this complex...
  • Opportunity compass with Chinese flag

    For big pharma, China is a shopper’s dream

    BioWorld
    Big pharma is increasingly shopping in China to fill its pipelines as it faces looming patent cliffs on major blockbusters coupled with growing pricing...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe